Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acurx Pharmaceuticals Inc (NQ: ACXP )

2.920 -0.030 (-1.02%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,555
Open 3.320
Bid (Size) 2.850 (10)
Ask (Size) 3.070 (1)
Prev. Close 2.950
Today's Range 2.860 - 3.320
52wk Range 2.330 - 4.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Recap: Acurx Pharmaceuticals Q1 Earnings
 
Via Benzinga

Performance

YTD
-31.14%
-31.14%
1 Month
+5.80%
+5.80%
3 Month
-18.89%
-18.89%
6 Month
-11.52%
-11.52%
1 Year
+15.42%
+15.42%

More News

Read More
A Preview Of Acurx Pharmaceuticals's Earnings
Via Benzinga
Acurx Pharmaceuticals's Earnings: A Preview
Via Benzinga
In The Queue: AcurX Pharmaceuticals Earnings…Here’s What Investors Need To Know Before Thursday ($ACXP)
Via AB Newswire
Exposures Product Safety
Race To The Cure: Here’s Why Acurx Pharmaceuticals Could Win The Battle To Treat C. difficile ($ACXP)
Via AB Newswire
Acurx Pharmaceuticals CEO Is Confident His Ibezapolstat Can Earn Front-Line Designation To Treat C. difficile…Here’s Why ($ACXP)
Via AB Newswire
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff
Via TheNewswire.com
Topics Death
Exposures Death Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Via Benzinga
Acurx Pharmaceuticals Surges 29% In August, Here’s Why The ACXP Bulls Expect Much More To Come ($ACXP)
Via AB Newswire
91 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)
Via AB Newswire
Exposures Product Safety
Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)
Via AB Newswire
Exposures Product Safety
90 Biggest Movers From Yesterday
Via Benzinga
Earnings Scheduled For March 17, 2022
Via Benzinga
Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals’ Phase 2b Antibiotic Candidate To Treat C. Difficile Shows 100% Cure And 100% Sustained Cure In Potentially Transformative Study (NASDAQ: ACXP)
Via AB Newswire
53 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)
Via AB Newswire
If A Santa Claus Rally Comes To Town, Expect Acurx Pharmaceuticals To Be On The Lead Sleigh…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
With A Phase 2b Trial In Progress, Acurx Pharmaceuticals May be The Most Undervalued Biotech On The Market…Here’s Why (NASDAQ: ACXP)
Via AB Newswire
Acurx Pharmaceuticals Stock Spikes 10% After Reaching Phase 2b Milestone Evaluating Ibezapolstat To Treat CDI (NASDAQ: ACXP)
Via AB Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.